Key result
Mfn2 reconstitution improves LVEF and inhibits mitochondrial fission in diabetic mice via ~1.8-fold higher expression.
Why the study?
Does targeting mitochondrial dynamics by regulating Mfn2 prevent or treat diabetic cardiomyopathy?
Does targeting mitochondrial dynamics by regulating Mfn2 prevent or treat diabetic cardiomyopathy?
Regulating Mfn2 to target mitochondrial dynamics represents a potential novel therapeutic strategy for diabetic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Mfn2 reconstitution may benefit diabetic cardiomyopathy; hypothesis-generating in mice and leaves open human translation.
Increasing evidence has implicated the important role of mitochondrial pathology in diabetic cardiomyopathy (DCM), while the underlying mechanism remains largely unclear. The aim of this study was to investigate the role of mitochondrial dynamics in the pathogenesis of DCM and its underlying mechanisms. Methods: Obese diabetic (db/db) and lean control (db/+) mice were used in this study. Mitochondrial dynamics were analyzed by transmission electron microscopy in vivo and by confocal microscopy in vitro. Results: Diabetic hearts from 12-week-old db/db mice showed excessive mitochondrial fission and significant reduced expression of Mfn2, while there was no significant alteration or slight change in the expression of other dynamic-related proteins. Reconstitution of Mfn2 in diabetic hearts inhibited mitochondrial fission and prevented the progression of DCM. In an in-vitro study, cardiomyocytes cultured in high-glucose and high-fat (HG/HF) medium showed excessive mitochondrial fission and decreased Mfn2 expression. Reconstitution of Mfn2 restored mitochondrial membrane potential, suppressed mitochondrial oxidative stress and improved mitochondrial function in HG/HF-treated cardiomyocytes through promoting mitochondrial fusion. In addition, the down-regulation of Mfn2 expression in HG/HF-treated cardiomyocytes was induced by reduced expression of PPARα, which positively regulated the expression of Mfn2 by directly binding to its promoter. Conclusion: Our study provides the first evidence that imbalanced mitochondrial dynamics induced by down-regulated Mfn2 contributes to the development of DCM. Targeting mitochondrial dynamics by regulating Mfn2 might be a potential therapeutic strategy for DCM.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2019) studied Diabetic cardiomyopathy. Intramyocardial injection of recombinant adenovirus encoding Mfn2 (Ad-Mfn2) vs. Control empty adenoviral vector (Ad-EV) was evaluated on Mitochondrial dynamics (fission/fusion) and cardiac function (LVEF, LVFS, E/A ratio) (p=<0.01). Mfn2 reconstitution via adenoviral delivery increased myocardial Mfn2 expression by 1.8-fold at 4 weeks, significantly inhibiting mitochondrial fission and improving LVEF and LVFS in db/db mice (P<0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: